Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte (INCY)
:INCY
INCY Analyst Ratings
Moderate Buy
6 Buy
8 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INCY Stock 12 Month Forecast
Average Price Target
$76.92
▲(6.67% Upside)
| Highest Price Target$100.00 | Average Price Target$76.92 | Lowest Price Target$52.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
Reiterated
02/12/25
TD Cowen
Reiterated
02/11/25
Citi
Reiterated
02/11/25
Truist Financial
Reiterated
02/11/25
Morgan Stanley
Reiterated
02/11/25
JMP Securities
Reiterated
02/11/25
Wells Fargo
Reiterated
02/10/25
Stifel Nicolaus
Reiterated
02/10/25
Bank of America Securities
Reiterated
02/10/25
RBC Capital
$70→$68
Hold
-5.70%
Downside
Reiterated
02/10/25
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Alnylam Pharma (NASDAQ: ALNY) and Nurix Therapeutics (NASDAQ: NRIX)
Jefferies
$84→$81
Buy
12.33%
Upside
Reiterated
02/10/25
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (NYSE: INSP), Vertex Pharmaceuticals (NASDAQ: VRTX) and Incyte (NASDAQ: INCY)
Leerink Partners
$100
Buy
38.68%
Upside
Reiterated
02/10/25
Incyte's Strong Q4 Performance and Promising Growth Outlook Earns 'Buy' RatingWe update our model for the quarter and 2025 guidance, the primary changes increasing 2025 Opzelura revenue from $606 mn to $650mn and FY25 GAAP R&D from $1.84bn to $1.95bn to both be within the guidance range. Overall, our PT remains at $100, and we maintain our OP rating.
BMO Capital
$52
Sell
-27.89%
Downside
Reiterated
01/13/25
Incyte's Strategic Challenges: Navigating Post-Jakafi Growth Gap and Limited Business Development Capacity
Oppenheimer
$82
Buy
13.72%
Upside
Reiterated
12/13/24
Oppenheimer reiterates Outperform Rating on Incyte (INCY)Oppenheimer analyst Jay Olson reiterated an Outperform rating and $82.00 price target on Incyte (NASDAQ: INCY).
Best Analysts Covering Incyte
Which Analyst Should I Follow If I Want to Buy INCY and Sell After:
1 Month
xxx
Success Rate
10/18 ratings generated profit
Average Return
+2.37%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +2.37% per trade.
3 Months
xxx
Success Rate
15/18 ratings generated profit
Average Return
+8.46%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +8.46% per trade.
1 Year
Success Rate
18/21 ratings generated profit
Average Return
+10.49%
reiterated a buy rating 13 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +10.49% per trade.
2 Years
xxx
Success Rate
18/22 ratings generated profit
Average Return
+10.53%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +10.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INCY Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
0
0
0
0
0
Buy
16
16
13
8
11
Hold
31
32
25
18
20
Sell
2
2
3
3
2
Strong Sell
0
0
0
0
0
total
49
50
41
29
33
Each month's total comprises the sum of three months' worth of ratings.
INCY Financial Forecast
INCY Stock Forecast FAQ
What is INCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte’s 12-month average price target is $76.92.
What is INCY’s upside potential, based on the analysts’ average price target?
Incyte has 6.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INCY a Buy, Sell or Hold?
Incyte has a consensus rating of Moderate Buy which is based on 6 buy ratings, 8 hold ratings and 1 sell ratings.
What is Incyte’s price target?
The average price target for Incyte is $76.92. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $52.00. The average price target represents 6.67% Increase from the current price of $72.11.
The highest analyst price target is $100.00 ,the lowest forecast is $52.00. The average price target represents 6.67% Increase from the current price of $72.11.
What do analysts say about Incyte?
Incyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of INCY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.